A5046139662- Tuberculosis Research and Epidemiology
- Mycobacterium research and diagnosis
- Infectious Diseases and Tuberculosis
- SARS-CoV-2 and COVID-19 Research
- Diagnosis and treatment of tuberculosis
- Pneumocystis jirovecii pneumonia detection and treatment
- COVID-19 Clinical Research Studies
- HIV Research and Treatment
- Biosimilars and Bioanalytical Methods
- Pneumonia and Respiratory Infections
- Immunodeficiency and Autoimmune Disorders
- Autophagy in Disease and Therapy
- Monoclonal and Polyclonal Antibodies Research
- Long-Term Effects of COVID-19
- SARS-CoV-2 detection and testing
- Herpesvirus Infections and Treatments
- Parasitic infections in humans and animals
- Amoebic Infections and Treatments
- Immune Cell Function and Interaction
- COVID-19 diagnosis using AI
- Bacillus and Francisella bacterial research
- Poxvirus research and outbreaks
- Immunotherapy and Immune Responses
- Congenital Anomalies and Fetal Surgery
- Microbial Metabolites in Food Biotechnology
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2025
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
2016-2025
Canadian Respiratory Research Network
2016
Translational Research Institute
2012-2015
Istituto Superiore di Sanità
2009-2010
Protective immunity to Mycobacterium tuberculosis (Mtb) remains poorly understood and the role of Mtb-specific CD8(+) T cells is controversial. Here we performed a broad phenotypic functional characterization in 326 subjects with latent Mtb infection (LTBI) or active TB disease (TB). were detected most (60%) patients few (15%) LTBI but similar magnitude. mostly EMRA (CD45RA(+) CCR7(-)), coexpressing 2B4 CD160, TEM (CD45RA(-) expressing lacking PD-1 CD160. The cytokine profile was not...
QuantiFERON®-TB Gold Plus (QFT-Plus) is the new generation of QuantiFERON-TB In-Tube test to identify latent tuberculosis infection (LTBI). QFT-Plus includes TB1 and TB2 tubes which contain selected Mycobacterium (Mtb) peptides designed stimulate both CD4 CD8 T-cells. Aim this study flow cytometric characterization specific T-cell responses Mtb antigens contained within QFT-Plus.We enrolled 27 active (TB) patients 30 LTBI individuals. Following stimulation with TB2, antigen-specific T-cells...
The QuantiFERON-TB Gold Plus (QFT-Plus) represents the new In-tube (QFT-GIT) to identify latent tuberculosis infection (LTBI). main differences is addition of a tube containing shorter peptides stimulating CD8 T-cells. Aim this study evaluate accuracy QFT-Plus compared with QFT-GIT in cross sectional individuals or without (TB). We enrolled 179 participants: 19 healthy donors, 58 LTBI, 33 cured TB and 69 active TB. were performed. two tests showed substantial agreement. Moreover we found...
The interaction of COVID-19 and tuberculosis (TB) are still poor characterized. Here we evaluated the immune response specific for Micobacterium (Mtb) SARS-CoV-2 using a whole-blood-based assay-platform in patients either with TB or latent infection (LTBI).
Background Subjects with immune-mediated inflammatory diseases (IMID), such as rheumatoid arthritis, tuberculosis infection (TBI), have a high probability of progressing to disease (TB). We aim characterize the impact IMID on immune response M. (Mtb) in patients TBI and TB disease. Methods enrolled without IMID. Peripheral blood mononuclear cells (PBMCs) were stimulated Mtb-derived epitopes (MTB300). By flow-cytometry, we identified Mtb-specific CD4 + T cytokine-producing or CD25 CD134...
Baricitinib seems a promising therapy for COVID-19. To fully-investigate its effects, we in-vitro evaluated the impact of baricitinib on SARS-CoV-2-specific-response using whole-blood platform.
ObjectivesTo characterize the kinetics of humoral and T-cell responses in rheumatoid arthritis (RA)-patients followed up to 4-6 weeks (T3) after SARS-CoV-2 vaccine booster dose.MethodsHealth care workers (HCWs, n = 38) patients with RA (n 52) completing messenger RNA vaccination schedule were enrolled at T3. In each cohort, 25 subjects sampled 5 (T1) 6 months (T2) from first dose. The response was assessed by measuring anti-receptor-binding domain (RBD) neutralizing antibodies,...
Abstract Mycobacterium tuberculosis ( Mtb ), the causative agent of (TB), has infected over 1.7 billion people worldwide and causes 1.4 million deaths annually. Recently, genome sequence analysis allowed reconstruction complex (MTBC) evolution, with identification seven phylogeographic lineages: four referred to as evolutionarily “ancient”, three “modern”. The MTBC strains belonging “modern” lineages appear show enhanced virulence that may have warranted improved transmission in humans...
The QuantiFERON-TB Gold Plus (QFT-Plus) is a new test for latent tuberculosis infection (LTBI) diagnosis, in which has been added tube containing shorter peptides stimulating CD8 T-cells and CD4-stimulating-peptides. Measurement of alternative biomarkers to Interferon-γ (IFN-γ) QFT-Plus may improve its sensitivity. inducible protein 10 (IP-10), proposed as (TB) biomarker. We aimed evaluate the IP-10 accuracy LTBI diagnosis. was performed 36 active TB, 31 16 healthy donors (HD). detected by...
There is an urgent medical need to differentiate active tuberculosis (ATB) from latent infection (LTBI) and prevent undertreatment overtreatment. The aim of this study was identify biomarker profiles that may support the differentiation between ATB LTBI validate these signatures.The discovery cohort included adult individuals classified in four groups: (n = 20), without prophylaxis (untreated LTBI; n after completion (treated healthy controls (HC; 20). Their sera were analyzed for 40...
When the Mpox virus (MPXV) began spreading globally in 2022, it became critical to evaluate whether residual immunity from smallpox vaccination provided cross-protection. To assess cross-immune response MPXV, we collected serum samples (n = 97) and PBMCs 30) healthy-donors, either born before 1974 reporting during childhood or after 1975 not vaccinated with Vaccinia (VACV)-based vaccines. We evaluated levels of anti-MPXV IgG neutralizing antibodies (Nabs) presence a T cell against MPXV....